HealthLeaders Media February 15, 2023
The models were authorized under an executive order by President Joe Biden to ‘complement’ drug cost-savings provisions in the Inflation Reduction Act.
KEY TAKEAWAYS
The Medicare $2 Drug List for chronic conditions such as high blood pressure and high cholesterol.
The Cell and Gene Therapy Access Model addresses an emerging – but often prohibitively expensive — area of drug development that can cost upwards of $1 million.
The Accelerating Clinical Evidence Model would develop payment methods for drugs approved under accelerated approval, in consultation with the FDA.
The Biden administration on Tuesday unveiled three drug cost-savings models for Medicare enrollees, including a plan to offer Medicare Part D enrollees about 150 generic drugs...
Today's Sponsors
Today's Sponsor